Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung

Histopathology

Volumn 33, Issue 2, 1998, Pages 123-128

  Zirbes, T K ^a   Lorenzen, J ^a   Baldus, S E ^a   Moenig, S P ^a   Wolters, U ^a   Ottlik, A ^a   Thiele, J ^a   Holscher A H ^a   Dienes, H P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Apoptosis; Bcl 2; P53; Pulmonary carcinoid tumours

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MALE; PRIORITY JOURNAL; TUMOR CELL;

ADULT; AGED; APOPTOSIS; BCL-X PROTEIN; CARCINOID TUMOR; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0031813645     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00466.x     Document Type: Article

References (29)

1. Barbareschi M, Tison V, Ferrero S et al. The problem of atypical carcinoid of the lung and other unusual neuroendocrine tumors. Cancer Ther. Contr. 1991; 2; 103-121.
2. Bernstein C, Mc Coey J. Lertzmann M. Recurrent bronchial carcinoid tumors. Chest 1989; 95; 693-694.
3. Bertelsen S, Aasted A, Lund C et al. Bronchial carcinoid tumors: A clinicopathologic study of 82 cases. Scand. J. Thorac. Cardiovasc. Surg. 1985; 19; 105-111.
4. Bonato M, Cerati M, Pagani A et al. Differential diagnostic patterns of lung neuroendocrine tumors: A clinicopathological and immunohistochemical study of 122 cases. Virchows Arch. A Pathol. Anal. 1992; 420; 201-211.
5. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J. Thorac. Cardiovasc. Surg. 1972; 64; 413-421.
6. Paladugu RR, Benfield JR, Pak HY, Ross RK, Teplitz RL. Bronchopulmonary Kultschitsky cell carcinomas. A new classification scheme for typical and atypical carcinoids. Cancer 1985; 55; 1303-1311.
7. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch. 1995; 425; 547-560.
8. Grote TH, Macon WR, Davis B, Greco FA, Johnson DH. Atypical carcinoid of the lung, a distinct clinicopathologic entity. Chest 1988; 93; 370-375.
9. Johnson LA, Lavin P, Moertel CG et al. Carcinoid: the association of histologic growth pattern and survival. Cancer 1983; 51; 882-889.
10. Hermanek P, Sobin LH, eds. UICC TNM Classification of Malignant Tumours. 4th edn. Berlin: Springer-Verlag, 1992: 80-81.
11. Valu M, Fabris GA, Dewar A, Hornall D, Sheppard MN. Atypical carcinoid tumor of the lung: a study of 33 cases with prognostic features. Histopathology 1994; 24; 363-369.
12. Böhm J, Koch S, Gais P, Jütting U, Präuer HW, Höfler H. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J. Pathol. 1996; 176; 402-409.
13. Costes V, Marty-Ane C, Picot MC et al. Typical and atypical bronchopulmonary carcinoid tumors: A clinicopathologic and Ki-67-labeling study. Hum. Pathol. 1995; 26; 740-745.
14. Padberg B-C, Woenckhaus J, Hilger G et al. DNA cytophotometry and prognosis in typical and atypical bronchopulmonary carcinoids. Am. J. Surg. Pathol. 1996; 20; 815-822.
15. El-Naggar AK, Ballance W, Karmir FWA et al. Typical and atypical bronchopulmonary carcinoids. A clinicopathologic and flow cytometric study. Am. J. Clin. Pathol. 1991; 95; 828-834.
16. Jones DJ, Hasleton PS, Moore M. DNA ploidy in bronchopulmonary carcinoid tumors. Thorax 1988; 43; 195-199.
17. Larsimont D, Kiss R, DeLaunoit Y, Melamed MR. DNA characterisation of the morphonuclear features and DNA ploidy of typical and atypical carcinoids and small cell carcinomas of the lung. Am. J. Clin. Pathol. 1490; 94; 378-383.
18. Yousem SA, Taylor SR. Typical and atypical carcinoid tumors of the lung: a clinicopathologic and DNA analysis of 20 tumors. Mod. Pathol. 1990; 3; 502-505.
19. Lohmann DR, Fesseler B, Pütz B et al. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res. 1993; 53; 5797-5801.
20. Da-Gong W, Johnston CF, Anderson N, Sloan JM, Buchanan KD. Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J. Pathol. 1995; 175; 397-401.
21. Barbareschi M, Girlando S, Mauri FA et al. Tumour suppressor gene products, proliferation and differentiation markers in lung neuroendocrine neoplasms. J. Pathol. 1992; 166; 343-350.
22. Coppola D, Clarke M, Landreneau R, Weyant RJ, Cooper D, Yousem SA. Bcl-2, p53, CD 44 and CD 44v6 isoform expression in neuroendocrine tumors of the lung. Mod. Pathol. 1996; 9; 484-490.
23. Brambilla E, Negoescu A, Gazzeri S et al. Apoptosis related factors p 53, bcl-2 and Bax in neuroendocrine lung tumors. Am. J. Pathol. 1996; 149; 1941-1452.
24. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. J. Immunol. Method. 1989; 125; 279-285.
25. Bobrow MN, Litt GJ, Shaughnessy KJ, Mayer PC, Conlon J. The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. J. Immunol Method. 1992; 150; 145-149.
26. Merz H, Malisius R, Mannweiler S et al. Methods in laboratory investigation, Immuno Max, a maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab. Invest. 1995; 71; 149-156.
27. Ansari B, Coates PJ, Greenstein BD, Haull PA. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J. Pathol. 1993; 170; 1-8.
28. Leoncini L, Del Vecchio MT, Megha T et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am. J. Pathol. 1993; 142; 755-763.
29. Czader M, Mazur J, Petterson M et al. Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived non-Hodgkin's lymphomas. Cancer 1996; 77; 1180-1188.